241 related articles for article (PubMed ID: 25433918)
1. Methotrexate revisited: considerations for subcutaneous administration in RA.
Jay R
Clin Rheumatol; 2015 Feb; 34(2):201-5. PubMed ID: 25433918
[TBL] [Abstract][Full Text] [Related]
2. Utilization of Subcutaneous Methotrexate in Rheumatoid Arthritis Patients After Failure or Intolerance to Oral Methotrexate: A Multicenter Cohort Study.
Branco JC; Barcelos A; de Araújo FP; Sequeira G; Cunha I; Patto JV; Oliveira M; Mateus MP; Couto M; Nero P; Pinto P; Monteiro P; Castelão W; Félix J; Ferreira D; Almeida J; Silva MJ
Adv Ther; 2016 Jan; 33(1):46-57. PubMed ID: 26724937
[TBL] [Abstract][Full Text] [Related]
3. Oral to subcutaneous methotrexate dose-conversion strategy in the treatment of rheumatoid arthritis.
Schiff MH; Sadowski P
Rheumatol Int; 2017 Feb; 37(2):213-218. PubMed ID: 28012023
[TBL] [Abstract][Full Text] [Related]
4. Inadequate response or intolerability to oral methotrexate: Is it optimal to switch to subcutaneous methotrexate prior to considering therapy with biologics?
Yadlapati S; Efthimiou P
Rheumatol Int; 2016 May; 36(5):627-33. PubMed ID: 26936262
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.
Müller RB; von Kempis J; Haile SR; Schiff MH
Semin Arthritis Rheum; 2015 Aug; 45(1):28-34. PubMed ID: 25895697
[TBL] [Abstract][Full Text] [Related]
6. Methotrexate and Rheumatoid Arthritis: Current Evidence Regarding Subcutaneous Versus Oral Routes of Administration.
Bianchi G; Caporali R; Todoerti M; Mattana P
Adv Ther; 2016 Mar; 33(3):369-78. PubMed ID: 26846283
[TBL] [Abstract][Full Text] [Related]
7. Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms.
Cipriani P; Ruscitti P; Carubbi F; Liakouli V; Giacomelli R
Clin Ther; 2014 Mar; 36(3):427-35. PubMed ID: 24612941
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial.
Braun J; Kästner P; Flaxenberg P; Währisch J; Hanke P; Demary W; von Hinüber U; Rockwitz K; Heitz W; Pichlmeier U; Guimbal-Schmolck C; Brandt A;
Arthritis Rheum; 2008 Jan; 58(1):73-81. PubMed ID: 18163521
[TBL] [Abstract][Full Text] [Related]
9. Methotrexate: a gold standard for treatment of rheumatoid arthritis.
Shinde CG; Venkatesh MP; Kumar TM; Shivakumar HG
J Pain Palliat Care Pharmacother; 2014 Dec; 28(4):351-8. PubMed ID: 25322199
[TBL] [Abstract][Full Text] [Related]
10. New autoinjector technology for the delivery of subcutaneous methotrexate in the treatment of rheumatoid arthritis.
Schiff M; Jaffe J; Freundlich B; Madsen P
Expert Rev Med Devices; 2014 Sep; 11(5):447-55. PubMed ID: 24934630
[TBL] [Abstract][Full Text] [Related]
11. Optimizing Methotrexate Treatment in Rheumatoid Arthritis: The Case for Subcutaneous Methotrexate Prior to Biologics.
Sharma P; Scott DG
Drugs; 2015 Nov; 75(17):1953-6. PubMed ID: 26474779
[TBL] [Abstract][Full Text] [Related]
12. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration.
Schiff MH; Jaffe JS; Freundlich B
Ann Rheum Dis; 2014 Aug; 73(8):1549-51. PubMed ID: 24728329
[TBL] [Abstract][Full Text] [Related]
13. Parenteral methotrexate for the treatment of rheumatoid arthritis.
Yazici Y; Bata Y
Bull Hosp Jt Dis (2013); 2013; 71 Suppl 1():46-8. PubMed ID: 24219041
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.
Li Z; Zhang F; Kay J; Fei K; Han C; Zhuang Y; Wu Z; Hsia EC
Int J Rheum Dis; 2016 Nov; 19(11):1143-1156. PubMed ID: 26259617
[TBL] [Abstract][Full Text] [Related]
15. Use of oral and subcutaneous methotrexate in rheumatoid arthritis patients in the United States.
Curtis JR; Zhang J; Xie F; Beukelman T; Chen L; Fernandes J; Ginsberg S; Spettell C; Yun H; Saag KG; Schiff M
Arthritis Care Res (Hoboken); 2014 Nov; 66(11):1604-11. PubMed ID: 24942466
[TBL] [Abstract][Full Text] [Related]
16. Bioavailability of higher dose MTX comparing oral and subcutaneous administration in patients with RA.
Rau R
J Rheumatol; 2005 Jul; 32(7):1412; author reply 1412-3. PubMed ID: 15996092
[No Abstract] [Full Text] [Related]
17. Subcutaneous administration of methotrexate at high doses makes a better performance in the treatment of rheumatoid arthritis compared with oral administration of methotrexate: A systematic review and meta-analysis.
Li D; Yang Z; Kang P; Xie X
Semin Arthritis Rheum; 2016 Jun; 45(6):656-62. PubMed ID: 26686022
[TBL] [Abstract][Full Text] [Related]
18. [Methotrexate for the treatment of rheumatoid arthritis in Japan--much more still remains to be resolved].
Suzuki Y
Nihon Rinsho; 2002 Dec; 60(12):2331-8. PubMed ID: 12510358
[TBL] [Abstract][Full Text] [Related]
19. Effects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritis.
Stamp LK; Barclay ML; O'Donnell JL; Zhang M; Drake J; Frampton C; Chapman PT
J Rheumatol; 2011 Dec; 38(12):2540-7. PubMed ID: 21965639
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD Trial.
Keystone EC; Genovese MC; Hall S; Bae SC; Han C; Gathany TA; Xu S; Zhou Y; Leu JH; Hsia EC
J Rheumatol; 2016 Feb; 43(2):298-306. PubMed ID: 26669912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
